James Paul Scopa - 25 Jun 2025 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Director
Signature
/s/ Lesley Ann Calhoun, as attorney-in fact for James Scopa
Issuer symbol
ALGS
Transactions as of
25 Jun 2025
Transactions value $
$0
Form type
4
Filing time
26 Jun 2025, 16:30:56 UTC
Previous filing
20 Jun 2025
Next filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Scopa James Paul Director C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO /s/ Lesley Ann Calhoun, as attorney-in fact for James Scopa 26 Jun 2025 0001356950

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +5.86K $0.00 5.86K 25 Jun 2025 Common Stock 5.86K $7.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.